&t Margaret Johnson ;em>REFERENCE: Lancet 2007; 370:39-48 MARGARET JOHNSON, Royal Free Hospital, London A new non-nucleoside reverse-transcriptase inhibitor has demonstrated its activity in patie
&t
Margaret Johnson
;em>REFERENCE: Lancet 2007; 370:39-48
MARGARET JOHNSON, Royal Free Hospital, London
A new non-nucleoside reverse-transcriptase inhibitor has demonstrated its activity in patients infected with HIV-1. TMC125, or etravirine, was compared with placebo in over 500 treatment-experienced patients in the DUET-2 trial, and Derek Thorne heard more from Margaret Johnson of the Royal Free Hospital in London.
[audio:https://www.audiomedica.com/podcasting/general_medicine/070808margaret_johnson.mp3]